Sandoz Group (OTCMKTS:SDZNY) Raised to “Strong-Buy” at Erste Group Bank

Sandoz Group (OTCMKTS:SDZNY) was upgraded by stock analysts at Erste Group Bank to a “strong-buy” rating in a note issued to investors on Thursday,Zacks.com reports.

Separately, Barclays raised shares of Sandoz Group from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, May 5th. Four analysts have rated the stock with a Strong Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Strong Buy”.

Sandoz Group Stock Down 3.0%

Shares of SDZNY stock opened at $85.14 on Thursday. The firm has a fifty day moving average of $85.86 and a two-hundred day moving average of $83.75. Sandoz Group has a 1-year low of $55.42 and a 1-year high of $94.15. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.18 and a quick ratio of 0.77.

Sandoz Group Company Profile

Sandoz Group (OTCMKTS:SDZNY) is a multinational pharmaceutical company focused on the development, manufacturing and commercialization of generic medicines and biosimilars. The company supplies off-patent small-molecule drugs as well as biologic alternatives intended to offer lower-cost therapeutic options across a range of clinical areas. Sandoz emphasizes access and affordability, positioning its portfolio to serve hospitals, pharmacies and health systems looking to expand patient access to essential therapies.

The company’s product offerings span conventional generics, complex and specialty generics, and a growing pipeline of biosimilar medicines.